Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

Last updated: October 25, 2024
Sponsor: Washington University School of Medicine
Overall Status: Active - Recruiting

Phase

N/A

Condition

Astrocytoma

Gliomas

Glioblastoma Multiforme

Treatment

Sonobiopsy

Research blood

Definity®

Clinical Study ID

NCT05281731
202202025
R01CA276174
  • Ages > 18
  • All Genders

Study Summary

This clinical study to evaluate sonobiopsy is significant because sonobiopsy will fundamentally enhance the clinician's insight into the molecular features of an intracranial lesion to tailor treatment approaches and optimize outcomes. In addition to the standard diagnostics of anatomic imaging and surgical histology, sonobiopsy has the potential to become the third pillar for brain tumor management by radically advancing the ability to easily and regularly acquire tumor genetic and molecular signatures. This enhanced capability will have a dramatic impact on patient survival and quality of life.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Must be newly diagnosed with a lesion in the brain with imaging characteristicsconsistent with glioblastoma multiforme. Scan must have occurred no more than 28days prior to enrollment.

  • Lesion must be > 3 cm in maximal dimension on MRI.

  • Lesion must be in the supratentorial space within 5 cm of the cortical surface.

  • Lesion must be gadolinium enhancing.

  • Low grade tumors and metastatic tumors

  • Recurrent brain tumors and/or radiation necrosis

  • Must be planning to undergo surgical resection of the tumor.

  • Must be at least 18 years old.

  • Patients with recurrent GBM who are planning to undergo surgical resection or laserablation of the recurrent tumor. Recurrence must be confirmed on MRI performed nomore than 28 days prior to enrollment.

Exclusion

Exclusion Criteria:

  • Contraindication to MRI.

  • Previous cranial surgery.

  • Previous history of cancer and/or cancer treatments.

  • Coagulopathy within 14 days of enrollment defined as PT/PTT outside of normalparameters and platelets < 100,000/mcL.

  • Physical skull defect of any kind.

  • Ferrous material in the scalp or skull.

  • Scalp or skin disease that limits contact with the ultrasound probe.

  • Enrolled in another clinical trial where intervention is administered prior tosurgery.

  • Known hypersensitivity to polyethylene glycol.

  • Known unstable cardiopulmonary condition (e.g. acute myocardial infarction, acutecoronary artery syndromes, worsening or unstable congestive heart failure, seriousventricular arrhythmias).

Study Design

Total Participants: 40
Treatment Group(s): 4
Primary Treatment: Sonobiopsy
Phase:
Study Start date:
April 18, 2022
Estimated Completion Date:
November 30, 2028

Connect with a study center

  • Washington University School of Medicine

    Saint Louis, Missouri 63110
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.